文献速递慢性肾脏病肾小球疾病

埃格列净与CKD合并糖尿病患者肾损伤、炎症及纤维化标志物的关联

Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes.
PubMed 文献 · Kidney Int Rep · 2021-06-05

本文为VERTIS RENAL试验的事后探索性分析,纳入2型糖尿病合并3期CKD患者,随机接受埃格列净(5或15 mg/d)或安慰剂,检测基线、26周和52周血浆标志物。结果显示埃格列净组KIM-1在26周和52周均较低,52周时eotaxin-1较高,KIM-1变化与UACR变化正相关,其他标志物无显著关联。

要点

  • 埃格列净可持续降低2型糖尿病合并3期CKD患者的肾小管损伤标志物KIM-1。
  • KIM-1降低不依赖基线eGFR或UACR,且其变化与UACR变化正相关。
  • 其他肾小管损伤、炎症、纤维化、氧化应激及内皮功能障碍标志物无显著变化。

核心结论

  • 在2型糖尿病合并3期CKD患者中,埃格列净与肾小管损伤标志物KIM-1的持续降低相关,且不依赖基线肾功能。

研究设计与样本

  • VERTIS RENAL试验的事后探索性分析,参与者随机接受埃格列净5或15 mg/d或安慰剂,并在基线、26周和52周采集血浆进行生物标志物分析。

主要发现

  • 与安慰剂相比,埃格列净组26周(P=0.044)和52周(P=0.007)血浆KIM-1水平较低,52周eotaxin-1较高(P=0.007)。
  • KIM-1变化与基线UACR或eGFR无交互作用(P交互>0.05)。
  • 在埃格列净组中,KIM-1变化与UACR变化呈正相关(P=0.0071)。
  • 其他肾小管损伤、炎症、纤维化、氧化应激及内皮功能障碍标志物未见显著关联。

临床怎么用

  • 对于2型糖尿病合并3期CKD患者,埃格列净可能通过降低肾小管损伤标志物KIM-1发挥肾脏保护作用。

局限性

  • 本研究为事后探索性分析,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes through mechanisms that are incompletely understood. In this exploratory post-hoc analysis of the VERTIS RENAL trial, we report the association between the SGLT2 inhibitor, ertugliflozin, and markers of kidney injury, inflammation, and fibrosis in participants with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD). METHODS: Participants were randomized to ertugliflozin (5 or 15 mg/d) or placebo, and plasma samples for biomarker analysis were collected at baseline, 26 weeks, and 52 weeks. RESULTS: Ertugliflozin-treated participants had lower plasma levels of kidney injury molecule-1 (KIM-1) at 26 weeks (P = 0.044) and 52 weeks (P = 0.007) and higher eotaxin-1 at 52 weeks (P = 0.007) postrandomization compared with placebo. The change in KIM-1 was not associated with the baseline urine albumin to creatinine ratio (UACR) or the estimated glomerular filtration rate (eGFR, P interaction > 0.05). Additionally, the change in KIM-1 was positively correlated with the change in UACR in participants treated with ertugliflozin (P = 0.0071). No other significant associations between ertugliflozin and changes in the markers of tubular injury, inflammation, fibrosis, oxidative stress, and endothelial dysfunction were observed. CONCLUSION: In conclusion, in participants with T2D and stage 3 CKD, ertugliflozin was associated with a sustained lowering of the tubular injury marker KIM-1 regardless of baseline kidney function.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Liu H, Sridhar VS, Lovblom LE, et al. Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes. Kidney Int Rep. 2021. PMID: 34386658. doi:10.1016/j.ekir.2021.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。